MALCOLM BRENNER to Graft Rejection
This is a "connection" page, showing publications MALCOLM BRENNER has written about Graft Rejection.
Connection Strength
0.402
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.137
-
CMV-induced augmentation of GVL effect may be mediated by cytokines. Bone Marrow Transplant. 1991 Jan; 7(1):69.
Score: 0.071
-
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
Score: 0.061
-
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9.
Score: 0.052
-
XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
Score: 0.022
-
Current role and status of bone marrow transplantation. Br J Hosp Med. 1989 Mar; 41(3):260-5.
Score: 0.016
-
[Therapeutic advances in bone marrow transplantation]. Clin Ter. 1987 Sep 15; 122(5):321-32.
Score: 0.014
-
Bone marrow transplantation in acute or chronic leukaemia. Acta Haematol. 1987; 78 Suppl 1:194-7.
Score: 0.013
-
Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol. 1986 Jun; 63(2):221-30.
Score: 0.013
-
T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:225-8.
Score: 0.004